Evotec stock edges lower as investors weigh recent results and low share price

Published on 09/10/2026 at 14:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock traded around EUR 3.13 on Xetra on September 10, 2026, only slightly below the session opening level. The biopharmaceutical group reported EUR 123.5 million in revenue in Q2 2026, down from EUR 133.1 million a year earlier.

Fotorealistisches Pharma-Labor mit Wissenschaftlern bei Wirkstoffscreening in moderner Biotech-Anlage — Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec stock (ISIN DE0005664809) traded at around EUR 3.13 on Xetra in early action on September 10, 2026, putting the biotechnology company’s shares marginally in the red compared with the previous close as investors digested recent quarterly figures and the depressed share price level.

Stock holds near EUR 3 mark

According to finanzen.ch on September 10, 2026, Evotec shares were last quoted at EUR 3.13 on Xetra, about 0.1 percent below the prior close, after having opened the session at EUR 3.16 and touched an intraday low of EUR 3.13.

In another intraday snapshot on September 10, 2026, the stock was reported at EUR 3.14 on Xetra, up roughly 0.2 percent from the previous closing level, highlighting how Evotec stock is currently oscillating narrowly around the EUR 3.10 mark rather than showing a pronounced directional move, as noted by finanzen.ch.

Quarterly figures show slight revenue decline

For a deeper look at the fundamentals behind the current valuation, investors focus on Evotec’s most recent quarterly report, which covers the second quarter of 2026 and remains within the relevant freshness window for today’s assessment.

According to Evotec’s investor relations information on its website, accessed via the company’s investor relations overview at Evotec, the company generated revenue of EUR 123.5 million in the second quarter of 2026, compared with EUR 133.1 million in the second quarter of 2025, corresponding to a year-over-year decline of around 7.2 percent.

In the same Q2 2026 reporting, Evotec recorded an adjusted EBITDA of EUR 18.4 million, versus EUR 22.8 million in the prior-year quarter, meaning operating earnings before interest, taxes, depreciation and amortization fell by about 19.3 percent year on year, as outlined in the company’s investor relations documentation accessed via Evotec.

The Q2 2026 report also indicated that Evotec’s net income attributable to shareholders came in at approximately EUR 4.2 million, down from around EUR 7.1 million in the second quarter of 2025, which translates into a decline of more than 40 percent year on year and underlines the current profitability pressure that the group faces, based on figures presented in the same investor relations material accessible via Evotec.

Guidance and investor perspective

Despite the declines in revenue and earnings in Q2 2026, Evotec confirmed its full-year 2026 guidance ranges for revenue and adjusted EBITDA in its latest communication, aiming for revenue in a corridor around the mid EUR 400 million region and adjusted EBITDA in a mid-double-digit million euro range, according to guidance comments summarized in the company’s investor relations overview at Evotec.

For retail investors, the combination of declining quarterly earnings and the reiterated guidance means the market must judge whether the current low share price adequately reflects near-term risks in Evotec’s discovery and development projects or whether the valuation already prices in a significant portion of operational challenges.

Evotec stock price and key data

As of September 10, 2026, Evotec stock’s reference quote on its primary listing venue Xetra can be taken as EUR 3.13, with the latest intraday values hovering close to that level and showing only small percentage changes during the trading session. Within this price context, the market capitalization remains constrained, reflecting investors’ cautious stance toward the company’s earnings trajectory and growth prospects.